Abstract:A preferential eEVAR protocol for acute AAA can decrease mortality and does not increase overall costs during initial treatment, but larger studies are needed to determine if these trends are statistically significant.
“…4 In our own report designed to define cost-effectiveness of the introduction of a preferential endovascular strategy in patients with AAAA, we found that in-hospital mortality dropped from 31% (historical open repair control group) to 18% (for endovascular repair of selected patients). 5 These results compare well with the literature and resulted in a local treatment strategy in which patients were virtually never denied treatment, regardless of their age.…”
For octogenarians, our liberal strategy of treating patients with AAAA was associated with satisfactory short- and long-term outcome, with no difference with regard to disease- or procedure-related morbidity between the younger and older group. Assuming an integrated system for managing AAAA is in place, advanced age is not a reason to deny patients surgery.
“…4 In our own report designed to define cost-effectiveness of the introduction of a preferential endovascular strategy in patients with AAAA, we found that in-hospital mortality dropped from 31% (historical open repair control group) to 18% (for endovascular repair of selected patients). 5 These results compare well with the literature and resulted in a local treatment strategy in which patients were virtually never denied treatment, regardless of their age.…”
For octogenarians, our liberal strategy of treating patients with AAAA was associated with satisfactory short- and long-term outcome, with no difference with regard to disease- or procedure-related morbidity between the younger and older group. Assuming an integrated system for managing AAAA is in place, advanced age is not a reason to deny patients surgery.
“…56 The cost savings obtained from decreased morbidity, mortality, and decreased LOS at the initial time of surgery is offset by the cost of the device, continued surveillance, and increased reintervention rates compared to open repair. [21][22][23][24] However, when it comes to traumatic aortic injuries, the difference in perioperative morbidity and mortality is larger compared with differences seen for EV for AAAs. Therefore, the cost savings is also significantly higher, especially when we factor in the cost associated with treating a patient who develops paraplegia, which can cost over $100,000 in the first year alone.…”
Section: Discussionmentioning
confidence: 99%
“…15,20 Although EV of AAAs has inconsistently shown to be cost effective, the mortality, morbidity (paraplegia rate) and LOS benefits are significantly greater for patients with BTAI than for elective aneurysm repair. 15,[21][22][23][24] Therefore, we postulate that the cost savings from EV repair of BTAIs would outweigh the cost of the device, surveillance, and reinterventions. Currently, there are no studies that have evaluated the cost effectiveness of EV in the setting of thoracic aortic injury.…”
EV repair of BTAIs offers a survival advantage as well as a reduction in major morbidity, including paraplegia, compared with OSR, and results in a reduction in costs at 1 year. As a result, from the cost-effectiveness point of view, EV is the DOMINANT therapy over OSR for these injuries.
“…A prospective cohort study by Kapma et al [54] utilising a preferential protocol favouring EVAR was compared to a historical group of patients treated with OR. It was found that treatment with EVAR was not more expensive than OR, however, the conclusions drawn are limited by the study design and small sample size [54].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.